Cardiff Oncology, Inc. (CRDF) 8-K Current Report — February 25, 2026

Filed: February 25, 2026

Health Care

Biological Products, (No Diagnostic Substances)

Cardiff Oncology, Inc. (CRDF) 8-K current report filed with SEC EDGAR on February 25, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 7.01: Regulation FD Disclosure

Cardiff Oncology, Inc. 8-K Feb 25, 2026 Event Analysis

Item 7.01 · Regulation FD Disclosure

• Cardiff Oncology (CRDF) conducting third-party investor/partner meetings using updated corporate slide presentation
• Presentation filed as Exhibit 99.1 — primary source for pipeline updates, data, or strategic positioning

+1 more insights

Other Cardiff Oncology, Inc. 8-K Filings

8-K Feb 24, 2026

Get deeper insights on Cardiff Oncology, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.